Company Profile

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâ€™s novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company

25-06-12	BiVictriX Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-05-27	Bivictrix Limited Announces Termination of Mrs. Susan Day Lowther as Director, Effective May 23, 2025	CI
25-05-27	BiVictriX Therapeutics plc Appoints Michael Glen Kauffman as Director, Effective May 23, 2025	CI
24-09-09	Bivictrix Therapeutics optimistic about BVX002 after in vivo testing	AN
24-09-09	BiVictriX's Ovarian Cancer Drug Conjugate Demonstrates Tumor Growth Inhibition	MT
24-08-12	Stocks rise as focus moves to economic data	AN
24-08-12	Bivictrix Therapeutics to delist as AIM offers insufficient liquidity	AN
24-08-12	AIM WINNERS & LOSERS: Global Petroleum jumps on potential Namibia deal	AN
24-08-12	BiVictriX Plans Delisting from London's AIM in September	MT
24-08-12	Bharti Global to build near 25% stake in BT	AN
24-08-01	Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Reports H1 Loss GBX-1.79	MT
24-08-01	BiVictriX Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-06-20	BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

24-09-11	BiVictriX Therapeutics plc Shares now trading on JP Jenkins	EQ
23-10-06	BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts	AQ
23-09-20	BiVictriX Therapeutics "looking really healthy" after positive first half	AQ
23-08-23	BiVictriX Therapeutics passes "exciting milestone" with US patent for BVX001	AQ
23-03-30	BiVictriX Therapeutics to "continue seeking out positive relationships"	AQ

Manager	Title	Age	Since
Tiffany Thorn CEO	Chief Executive Officer	39	2015-12-31
Adrian Howd DFI	Director of Finance/CFO	54	2023-10-02
Alison Halsall SEC	Corporate Secretary	-	2023-10-12

Director	Title	Age	Since
Tiffany Thorn BRD	Director/Board Member	39	2015-12-31
Susan Lowther BRD	Director/Board Member	67	2021-09-21
William Paris BRD	Director/Board Member	75	2021-09-21

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-09-01	Robert Hawkins	Sell	Director	20,000	0.0242%
24-09-01	Robert Hawkins	Buy	Director	20,000	0.0242%
24-08-12	Susan Lowther	Free	Director	200,000	0.2423%

BiVictriX Therapeutics plc Stock

Stocks

BVX

GB00BNXH3K91

Biotechnology & Medical Research

Latest news : BiVictriX Therapeutics plc

Press Releases: BiVictriX Therapeutics plc

Quotes and Performance

Managers and Directors: BiVictriX Therapeutics plc

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIVICTRIX THERAPEUTICS PLC	+17.65%	+33.33%	-	-	10.49M
LONZA GROUP AG	-0.57%	+1.40%	+3.09%	+7.35%	50.35B
REVOLUTION MEDICINES, INC.	+0.55%	-2.88%	+382.07%	+593.81%	39.32B
IQVIA HOLDINGS INC.	+0.13%	-0.19%	+29.79%	-6.00%	34.69B
BEONE MEDICINES AG	+0.86%	-0.78%	+21.58%	+56.15%	34.08B
CELLTRION, INC.	-1.31%	-3.03%	+2.51%	+25.24%	26.63B
ASCENDIS PHARMA A/S	+0.13%	-0.52%	-	-	16.49B
MEDPACE HOLDINGS, INC.	+1.13%	-1.85%	+67.36%	+120.46%	15.31B
EUROFINS SCIENTIFIC SE	+0.52%	+3.28%	+14.90%	+17.91%	13.8B
ICON PUBLIC LIMITED COMPANY	+1.13%	-0.44%	+12.34%	-31.79%	12.87B
Average	+2.01%	-0.82%	+66.70%	+97.89%	27.06B
Weighted average by Cap.	+0.14%	-0.73%	+81.09%	+122.36%